ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 2	2026-06-11		NCT06224673

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Ambrx, Inc.	2
Laura Huppert, MD, BA	2

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
University of California, San Francisco	San Francisco	United States	294

Clinical trials